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Dalla Man, Chiara, Andrea Caumo, Rita Basu, Robert Rizza,
Gianna Toffolo, and Claudio Cobelli. Measurement of selective effect
of insulin on glucose disposal from labeled glucose oral test minimal
model. Am J Physiol Endocrinol Metab 289: E909–E914, 2005. First
published June 21, 2005; doi:10.1152/ajpendo.00299.2004.—The oral
glucose minimal model (OMM) measures insulin sensitivity (SI) and
the glucose rate of appearance (Ra) of ingested glucose in the presence
of physiological changes of insulin and glucose concentrations. How-
ever, SI of OMM measures the overall effect of insulin on glucose
utilization and glucose production. In this study we show that, by
adding a tracer to the oral dose, e.g., of a meal, and by using the
labeled version of OMM, OMM* to interpret the data, one can
measure the selective effect of insulin on glucose disposal, S*I.
Eighty-eight individuals underwent both a triple-tracer meal with the
tracer-to-tracee clamp technique, providing a model-independent ref-
erence of the Ra of ingested glucose (Ra mealref ) and an insulin-modified
labeled intravenous glucose tolerance test (IVGTT*). We show that
OMM* provides not only a reliable means of tracing the Ra of
ingested glucose (Ra meal) but also accurately measures S*I. We do so
by comparing OMM* Ra meal with the model-independent Ra mealref
provided by the tracer-to-tracee clamp technique, while OMM* S*I is
compared with both SI* ref, obtained by using as known input Ra mealref ,
and with S*I measured during IVGTT*.
insulin action; glucose utilization; tracer-to-tracee activity clamp;
intravenous glucose tolerance test; oral glucose tolerance test
THE ORAL MINIMAL MODEL METHOD can simultaneously measure
insulin secretion, insulin action, and the rate of glucose appear-
ance after meal or glucose ingestion (3, 6, 11, 12). In particular,
the oral glucose minimal model (OMM) measures insulin
sensitivity (SI), as well as the rate of appearance of ingested
glucose (Ra meal) (11, 12). One limitation of the SI index
measured by OMM is that SI is a composite index, i.e., it
measures the overall effect of insulin to stimulate glucose
uptake and inhibit glucose production. At least in theory, the
individual contribution of insulin’s ability to stimulate glucose
uptake can be measured if a glucose tracer is added to the meal.
If so, labeled glucose oral data, analyzed by means of an oral
labeled minimal model, can provide an estimate of SI (S*I)
reflecting glucose disposal only. This would be reminiscent of
the approach that previously led our group to propose the
labeled intravenous glucose tolerance test (IVGTT) and its
interpretation with the labeled minimal model (10, 14).
The aim of this study is to develop and validate an oral
labeled minimal model (OMM*). We show that OMM* pro-
vides reliable estimates of disposal S*I and Ra meal. To validate
OMM*, we took advantage of a unique data set (11) containing
88 individuals who underwent a triple-tracer labeled meal, as
well as a labeled IVGTT (IVGTT*). The triple-tracer labeled
meal, thanks to the use of the tracer-to-tracee clamp technique,
provided a model-independent reference for the appearance
rate of ingested glucose (Ra mealref ) (4). Ra mealref was then used as a
known input of a model of labeled glucose kinetics. This
model, denoted as reference tracer model (RM*), was identi-
fied from labeled meal data and yielded a reference measure of
disposal insulin sensitivity, SI*ref. OMM* is validated by com-
paring OMM*-based estimates of S*I and Ra meal to SI*ref and
Ra mealref , respectively. Validation is further strengthened by com-
paring OMM* S*I with the IVGTT* S*I measured in the same
subjects with the traditional labeled minimal model.
METHODS
Data
The database consisted of 88 normal subjects [46 males and 42
females: age 58 2 yr (range 19–87); body wt 77 2 kg (range
53–129); BMI 26.71 0.1 kg/m2 (range 20–35); fasting glucose
92.07  0.7 mg/dl (range 77.29–105.12)] who received both a
triple-tracer mixed meal and an IVGTT*.
Labeled mixed meal. The triple-tracer mixed meal (10 kcal/kg: 45%
carbohydrate, 15% protein, 40% fat) contained 1  0.02 g/kg glucose.
The meal was labeled with [1-13C]glucose (G*), thus allowing us to
derive the exogenous, i.e, coming from the meal, glucose (Gmeal) as
Gmeal G*  1 1
zmeal
 (1)
where zmeal is the tracer-to-tracee ratio in the meal. Plasma samples
were collected at 120, 30, 20, 10, 0, 5, 10, 15, 20, 30, 40, 50,
60, 75, 90, 120, 150, 180, 210, 240, 260, 280, 300, 360, and 420 min.
Figure 1, A–C, left, shows mean glucose, exogenous glucose, and
insulin plasma concentration curves. Beginning at time 0, [6-3H]glu-
cose was infused intravenously at a variable rate, mimicking Ra meal.
[6,6-2H2]glucose was also infused as part of a separate protocol.
Because the ratio in plasma between [6-3H]glucose and [1-13C]glu-
cose was maintained almost constant (Fig. 2A), Steele’s model pro-
vided an essentially model-independent estimate of the Ra of ingested
tracer (Ra meal* ref ) (4); total Ra mealref was then calculated from Ra meal* ref (Fig.
2B) as
Ra mealref  Ra meal* ref  1 1
zmeal
 (2)
Labeled intravenous glucose tolerance test. The IVGTT* consisted
of a 330 mg/kg glucose bolus at time 0 labeled with [6,6-2H2]glucose,
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followed by a short insulin infusion of 0.02 U/kg between 20 and 25
min. Plasma samples were collected at 120, 30, 20, 10, 0, 2,
4, 6, 8, 10, 15, 20, 22, 25, 26, 28, 31, 35, 45, 60, 75, 90, 120, 180, and
240 min. Figure 1, A–C, right, shows mean glucose, exogenous
glucose, and insulin plasma concentration.
Models
Oral minimal models. For the sake of clarity, a brief description of
the “cold” (i.e., unlabeled) oral minimal models (11, 12) precedes the
presentation of the new “hot” (i.e., labeled) OMM*. This is done not
only because the two oral minimal models hinge on the same mono-
compartmental structure of glucose kinetics, but also because they
share the exogenous glucose input, i.e, Ra meal. Denoting by G the total
plasma glucose concentration, the rate of glucose disappearance (Rd)
and the net hepatic glucose balance (NHGB) (Fig. 3, left) model
equation following Ref. 5 is
G˙ t
 Rdt NHGBt Ra mealt
V
; G0 Gb (3)
where V is the distribution volume.
By assuming for Rd and NHGB the functional description proposed
in Ref. 5, one obtains OMM:
G˙ t  SG Xt  Gt SG  Gb Ra meal,tV G0 Gb
X˙ t  p2  Xt p3  It Ib X0 0
(4)
where SG is fractional (i.e., per unit distribution volume) glucose
effectiveness measuring glucose ability per se to promote glucose
disposal and inhibit NHGB, I is plasma insulin concentration, X is
insulin action on glucose disposal and production, with p2 and p3 rate
constants describing its dynamics and magnitude; b denotes basal
values. Ra meal is described as a piecewise-linear function with known
break point ti and unknown amplitude i:
Ra meal,t
 i1 i i1ti ti1 t ti1 per ti1 t ti i 1. . .8
0
(5)
with  denoting [1, 2,. . .8]T.
Fig. 1. Mean concentration of plasma glucose, exogenous glu-
cose, and insulin during meal (left) and intravenous glucose
tolerance test (IVGTT; right) in normal subjects (n  88).
Fig. 2. Clamped tracer-to-tracee ratio [6-3H]glucose/[1-13C]glucose (A) and
model-independent reference of the rate of appearance of tracer glucose
(Ra mealref ; B).
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 V dl  kg1  min1 per 	U/ml (6)
Labeled oral minimal model. OMM is unable to distinguish the
individual contribution of glucose production and disposal. To over-
come this limitation, a glucose tracer is administered orally and
unlabeled glucose and plasma concentrations of the glucose tracer are
measured. OMM* relies on Gmeal (eq. 1), and model equation is
G˙ mealt
 Rd mealt Ra mealt
V*
; Gmeal0 0 (7)
where Rd meal is the Rd of Gmeal. By assuming for Rd meal the same
functional description proposed previously (10) and for Ra meal the
parametric description of Eq. 5, one obtains OMM* (Fig. 3, middle).
Model equations are
G˙ mealt  S*G X*t  Gmealt Ra meal,tV* Gmeal0 0
X˙ *t  p*2  X*t p*3  It Ib X*0 0
(8)
where S*G is fractional (per unit distribution volume) glucose effec-
tiveness measuring glucose ability per se to promote glucose disposal
and X* insulin action on glucose disposal with p*2 and p*3 rate
constants describing its dynamics and magnitude, respectively.





 V dl  kg1  min1 per 	U/ml (9)
Because OMM* and OMM share Ra meal, the two models were
identified simultaneously (see Identification).
Reference-labeled model. The validation of OMM* estimates of Ra
meal and S*I was accomplished by using the following rationale. As
mentioned in Data, during the labeled meal, two additional tracers
were infused intravenously. In particular, [6-3H]glucose was infused
to clamp the ratio between concentrations in plasma of [6-3H]glucose
and ingested glucose tracer. This allowed us to derive reliable and
virtually model-independent estimates of Ra meal (4). This estimate,
denoted Ra mealref , was used not only as a reference with which OMM*
estimate of Ra meal was compared but also as a known input of a model
with the same structure of OMM* (Fig. 3, right):
G˙ mealt
 Rd mealref t Ra mealref t
V*ref
; Gmeal0 0 (10)
which becomes
G˙ mealt  SG* ref X* reft  Gmealt Ra mealref tV * ref Gmeal0 0
X˙ * reft p2* ref  X* reft p3* ref  It Ib X* ref0 0
(11)
By identifying this model, denoted as reference-labeled model
(RM*), from Gmeal and insulin data we were able to obtain reference
values for OMM* parameters (indicated by ref), in particular for S*I
(see Identification). Comparison between SI* ref, estimated with RM*,
and S*I, provided by OMM*, allowed OMM* validation.
IVGTT* minimal models. IVGTT* data were interpreted with the
classic single-compartment IVMM (5) and with the labeled two-
compartment minimal models (IVMM*) (14), thus obtaining an esti-
mate of SI and S*I in the same subjects. This, in addition to providing
a one-to-one comparison of IVGTT* S*I vs. OMM* S*I, allows us to
examine the relationship between SI and S*I in IVGTT and meal.
Identification
Identifiability. Because OMM* (like OMM) is a priori nonidentifi-
able, the a priori knowledge necessary for its identification was obtained
from RM*. OMM* was thus identified by fixing V* and S*G to the mean
values obtained with RM*, i.e., V*  V * ref, S*G  SG* ref. Mean values
can safely be used because they are normally distributed (see RE-
SULTS). At variance with OMM, where a Bayesian prior on p2 was
needed to improve numerical identifiability, OMM* takes advantage
of the fact that it shares Ra meal with OMM. The simultaneous
identification of OMM* and OMM from two measurements (Gmeal
and G) relaxes the necessity of using Bayesian priors for p2 and p*2. A
constraint (11, 12) was imposed to guarantee that the area under the
estimated Ra meal equals the total amount of ingested glucose, D,
multiplied by the fraction that is actually absorbed, f. Because f-values
estimated with RM* were not normally distributed (RESULTS), f was
Fig. 3. Left: oral minimal model (OMM). Middle: labeled oral minimal model (OMM*). Right: reference-labeled model (RM*). In OMM and OMM*, Ra meal
is described with a parametric model, which must be identified from the data. In RM*, input is model independent Ra mealref , reconstructed by tracer-to-tracee clamp
technique.
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fixed to the median of RM*: f  f m-ref. Finally, oral tracer measure-
ments provided information as to when Ra meal began to rise in each
subject. If tracer concentration is zero up to time ti and is different
from zero at time ti
1, then one can safely assume that Ra meal is zero
up to ti.
Parameter estimation. All models were numerically identified by
nonlinear least squares (7, 9), as implemented in SAAM II [Simula-
tion Analysis and Modeling software (2)]. Measurement error was
assumed to be independent, gaussian, with zero mean and known
constant standard deviation. Insulin concentration is the model-forc-
ing function and is assumed to be known without error.
Statistical Analysis.
Data are presented as means  SE. Two-sample comparisons were
done by Wilcoxon signed rank test, and a Shapiro-Wilk test was used
to verify whether parameters were normally distributed (significance
level set to 5%). Pearson’s correlation was used to evaluate univariate
correlation.
RESULTS
Parameter estimates of RM*, OMM*, and OMM (simulta-
neously identified), IVMM*, and IVMM are shown in Table 1
(means  SE) with their precision.
RM*. RM* parameters were estimated with good precision,
and their mean values are SG*ref  0.0118 min1, V*ref  1.60
dl/kg, p2*ref  0.039 min1, and SI*ref  9.24 104
dl kg1 min1 per 	U/ml. The fraction of ingested glucose
that reaches plasma, calculated as the ratio between area
under Ra mealref and ingested dose, was f ref  0.89. Parameters
SG*ref, V*ref were normally distributed (P values not significant
by Shapiro-Wilk test), although f ref was not (median value
f m-ref  0.90).
OMM* and OMM. The mean profile of Ra meal, recon-
structed by simultaneously identifying OMM* and OMM, is
shown in Fig. 4. Of note, Ra meal was virtually superimposable
(data not shown) to that reconstructed by identifying OMM
alone (11).
OMM* and OMM parameters were S*I  9.64 104
dl kg1 min1 per 	U/ml, p*2  0.043 min1, SI  12.24
104 dl kg1 min1 per 	U/ml, and p2  0.011 min1. This
estimate of SI was not significantly different from that obtained
in Eq. 11 by fitting OMM to total glucose concentration alone,
where we found SI  11.68  104 dl kg1 min1 per
	U/ml. The correlation between the two sets of SI estimates is
very high: r  0.96, P  0.001.
IVMM* and IVMM. S*I and SI were 11.59 and 6.91 104
dl kg1 min1 per 	U/ml, respectively.
OMM* vs. RM*. A good agreement was found between
OMM* Ra meal and Ra mealref (Fig. 4). S*I provided by OMM* and
SI* ref were well correlated (r  0.80, P  0.0001; Fig. 5A), and
their mean values were not significantly different (9.64 vs.
9.24  104 dl kg1 min1 per 	U/ml). To quantify how
sensitive the OMM/OMM* estimate of SI and S*I to the
assumptions made on V, V*, SG, S*G, and f were, we used
multiple regression analysis between the percentage deviation
of SI (S*I) and the percentage deviation of V, SG, and f (V*, S*G,
f). We found that the percentage deviations of f and SG explain
the deviation in SI estimate (0.685, P  0.0001), although the
deviation of V doesn’t contribute significantly to the regres-
sion. Conversely, the percentage deviations of f, S*G, and V*
explain the deviation in S*I estimate (0.747, P  0.0001).
OMM* vs. IVMM*. Correlation between IVMM* and
OMM* S*I was significant (r  0.67, P  0.0001; Fig. 5B) but
their values were significantly different (9.64 vs. 11.59 104
dl kg1 min1 per 	U/ml).
SI vs S*I. The relationship between SI and S*I is different
during meal and IVGTT. With the oral minimal models, one
had 12.24 vs. 9.64  104 dl kg1 min1 per 	U/ml, with
SI  S*I in 81% of the subjects, although for the IVGTT SI was
lower than S*I on average (SI  6.91 vs. S*I  11.59  104
dl kg1 min1 per 	U/ml) and was so in 90% of the
subjects.
DISCUSSION
The OMM method was developed to measure SI under
physiological conditions, e.g., a meal or OGTT (12). In addi-
Table 1. Parameter estimates of RM*, OMM*, and OMM (simultaneously identified), OMM
(separately identified), IVMM*, and IVMM
SG, min1
SI, 104 dlkg1min1
per 	U/ml V, dl/kg p2, min1
RM* 0.01180.0004 (25) 9.240.63 (22) 1.600.04 (8) 0.0390.004 (36)
OMM* 0.0118† 9.640.80 (12) 1.60† 0.0430.005 (46)
OMM 0.025† 12.240.68 (8) 1.45† 0.0110.004 (21)
OMM (separately identified) 0.025† 11.680.3 (7) 1.45† 0.0110.005 (15)
IVMM* 0.00730.0003 (21) 11.590.88 (15) 1.080.03 (14) 0.1010.007 (35)
IVMM 0.0190.0004 (32) 6.910.46 (12) 1.620.02 (5) 0.0330.002 (16)
Values are means  SE, with their precision in parantheses (% coefficient of variation). RM*, reference tracer model; OMM*, labeled version of oral glucose
minimal model; OMM, oral glucose minimal model; IVMM*, labeled two-compartment intravenous minimal model; IVMM, intravenous minimal model.
†Parameters fixed to reference values.
Fig. 4. Ra meal reconstructed by OMM* is shown against Ra mealref of Fig. 2B.
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tion, OMM can simultaneously estimate the Ra in plasma of the
ingested glucose, Ra meal. The validity of OMM SI and Ra meal
was recently established (11). However, OMM SI, although it
is an extremely useful index, is a composite measure of insulin
action on both glucose production and disposal. Our goal here
was to develop a method that specifically measured the ability
of insulin to stimulate glucose disposal in physiological con-
ditions. To do this, a tracer was added to the meal, and a
labeled OMM (OMM*) was developed. The validity of OMM*
S*I and Ra meal was assessed by comparing these values to
reference values SI* ref and Ra mealref , obtained in the same 88
subjects by means of multiple tracer infusions (4). In addition,
S*I calculated with OMM* was compared with that obtained
from a labeled insulin-modified IVGTT (IVGTT*) performed
in the same 88 individuals.
The Ra meal profile obtained with OMM* was very similar to
Ra mealref (Fig. 4). This is an important result, because due to the
experimental conditions (i.e., a tracer-to-tracee clamp), Ra mealref
provided an essentially model-independent measure of the
glucose Ra. S*I obtained by OMM* was also very similar to
reference values: S*I  9.64  0.80  104 vs. SI*ref  9.24 
0.63  104 dl kg1 min1 per 	U/ml, with a satisfactory
correlation between the two (r  0.80, P  0.0001; Fig. 5A).
However, from Fig. 5, differences exist at the individual level,
thus indicating that OMM* is more robust in population rather
than individual studies.
The addition of a tracer to the meal, besides allowing
segregation of exogenous component, Gmeal, of plasma glucose
concentration G, and thus estimation of insulin sensitivity on
glucose disposal, also has beneficial effects on the numerical
identifiability of OMM* (and OMM). In fact, OMM*, which is
based on Gmeal data, shares Ra meal with OMM, which is based
on G data. Thus, for its identification, the unlabeled plasma
glucose concentration data G can also be exploited by simul-
taneously identifying OMM. By doing so, the number of
available data doubles, although the number of parameters
increases by only two (i.e., from 10 parameters with OMM*
alone to 12 with both OMM* and OMM). The improvement in
numerical identifiability allowed estimation of p*2 and p2 in
each individual without having to resort to Bayesian priors as
in Refs. 11 and 12. However, parameters V, V*, SG, S*G, and f
still need to be fixed to population values derived from the
reference model. To quantify how sensitive the OMM/OMM*
estimate of SI and S*I to the assumptions made on these
parameters were, we investigated, by multiple regression anal-
ysis, the relationship between their percentage deviation and
that of SI and S*I. We found that the percentage deviations of f
and SG explain the deviation in SI estimate (0.685, P 
0.0001), whereas the deviation of V doesn’t contribute signif-
icantly to the regression. The percentage deviations of f, S*G,
and V* from the fixed values explain the deviation in S*I
estimate (0.747, P  0.0001).
It is of interest to compare S*I with OMM* and IVGTT*. The
two estimates showed a significant correlation, r  0.67, P 
0.0001 (Fig. 5B), although the latter measure was significantly
higher: 11.59 vs. 9.64  104 dl kg1 min1 per 	U/ml.
The relationship between the cold and hot estimates of SI in
IVGTT vs. meal is worth commenting on. The IVGTT results
observed in the present 88 subjects are consistent with those
previously reported in smaller-size studies (8, 10, 14). SI was
lower than S*I in 90% of the subjects: SI  6.91  104 vs.
S*I  11.59  104 dl kg1 min1 per 	U/ml. This relation-
ship is clearly unphysiological, because SI measures the overall
effect of insulin on both glucose disposal and production,
whereas S*I measures only the effect of insulin on disposal; by
definition, SI should be equal to or greater than S*I. Possible
reasons for this unexpected pattern have been discussed in Ref.
8. The relationship between SI and S*I improves dramatically
with the OMM, SI  12.24  104 vs. S*I  9.64  104
dl kg1 min1 per 	U/ml, with SI  S*I in 81% of the
subjects. However, SI was still less than S*I in 19% of the
subjects. It is likely that the improved performance of the oral
minimal models stems from the fact that the minimal model
assumptions are more tenable during the gentle meal than
during the massive IVGTT perturbation, particularly those
concerning the description of how NHGB is controlled by
glucose and insulin, which are embodied in both cold models.
However, the finding that S*I was greater than SI in 19% of the
subjects also calls for a revision of this functional description
for a meal perturbation.
A comment on the relationship between p2 and p*2 in IVGTT
and meal, as well as on the difference between intravenous and
oral values, is also in order. During both IVGTT and meal, p2
Fig. 5. OMM* insulin sensitivity (S*I ): correlation with S*I estimated from
RM* (A) and from IVMM* (B).
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is approximately one-third of p*2 (Table 1). This means that
insulin action on the liver has a slower dynamic than insulin
action on glucose utilization, and, in all likelihood, the under-
lying assumption of the classic minimal model, that insulin
action on glucose production has the same dynamics of insulin
action on glucose utilization, is probably not entirely correct.
Moreover, the difference found in p2 and p*2 values during
IVGTT and meal can be explained by considering the differ-
ences between the two tests. During IVGTT, glucose and
insulin explore a wider range of values than during the meal
(G: 90–300 vs. 90–170 mg/dl; I: 4–120 vs. 4–60 	U/ml), thus
possibly uncovering some parameter nonlinearities (1, 13).
In conclusion, OMM* provides a means of assessing both
Ra meal and S*I after the ingestion of a carbohydrate-containing
meal. Because OMM is simultaneously identified, this ap-
proach also permits assessment of the overall effect of insulin
on glucose production and disposal (SI). Furthermore, when
the labeled and unlabeled oral minimal models are combined
with the oral C-peptide minimal model (6, 15), insulin secre-
tion and -cell function indexes can also be measured at the
same time. However, although in the present study good
performance of the method was observed in a wide range of
glucose tolerance (SI: 1.52 30.40 104 dl kg1 min1 per
	U/ml), further studies in diabetic individuals with abnormalities
in insulin secretion and action of various degrees of severity are
needed to better define the domain of validity of the model.
Finally, because insulin action appears to be dependent on the
pattern of insulin (1, 13), future studies will be required to
determine whether the ability of insulin to stimulate glucose
uptake and suppress glucose production in the presence of the
continuously changing insulin concentrations observed after a
meal is the same as that observed in the presence of different
insulin profiles (e.g., during a hyperinsulinemic clamp).
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